

## Financial Tear Sheet

### Company Profile

Merus discovers and develops differentiated therapeutics aimed at substantially prolonging the lives of cancer patients. It is our strategy to use the power of bispecific antibody engineering and advanced screening technologies to develop biopharmaceuticals that engage the power of the immune system to kill tumor cells.

### Share Performance

MRUS (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$24.40
Change (%)	▼ 0.24 (0.97%)
Volume	23,256
52 Week Low	\$13.30
Market Cap	\$557,472,362
Rolling EPS	-5.00
PE Ratio	0
Shares Outstanding	22,624,690
Data as of 07/17/18 3:59 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

### News & Events

Date	Title
07/05/18	Merus Announces Annual Meeting of Shareholders
05/31/18	Merus to Present at the Jefferies 2018 Healthcare Conference

There are currently no events scheduled.

05/24/18 Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors

## SEC Filings

Filing Date	Form
07/05/18	6-K
07/02/18	6-K
06/19/18	SC 13G/A
05/21/18	CT ORDER

## Supervisory Board

Ton Logtenberg, Ph.D	CEO, Executive Director
Mark Iwicki	Chairman, Non-Executive Director
Anand Mehra, M.D.	Non-Executive Director
Lionel Carnot	Non-Executive Director
John de Koning, Ph.D.	Non-Executive Director
Gregory Perry	Non-Executive Director

## Primary IR Contact

Kimberly Minarovich  
Argot Partners  
Phone: 1 212-600-1902  
E-mail: [kimberly@argotpartners.com](mailto:kimberly@argotpartners.com)

## Management Board

Ton Logtenberg, Ph.D	CEO
Shelley Margetson	CFO